An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type

Trial Profile

An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms VOLFI
  • Most Recent Events

    • 12 Sep 2017 Results assessing efficacy and tolerability of oxaliplatin + irinotecan + fluorouracil + folinic acid [FOLFOXIRI] + panitumumab versus that of FOLFOXIRI chemotherapy alone in patients with metastatic, RAS wild-type, non-resectable colorectal cancer, were presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Status changed from recruiting to active, no longer recruiting, according to results presented at the 42nd European Society for Medical Oncology Congress.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top